Mandimycin is structurally similar to the last-line-of-defense antifungal amphotericin B, another glycosylated polyene macrolide. But instead of binding to ergosterol in the fungal cell membrane ...

Fungal infections in India pose public health risks, with growing concerns of drug resistance, especially in vulnerable ...

Mandimycin, which targets a different essential fungi cell resource than other antifungal drugs, should harm other cell types as collateral — but doesn’t.

A novel approach combines RNA interference (RNAi) with nanomedicine, using siRNAs packaged with Amphotericin B in anionic liposomes to target and inhibit fungal growth.

such as the clinically used agent amphotericin B. The authors used animal models of infection to test mandimycin against a range of fungal pathogens, including multidrug-resistant Candida auris (a ...

Market OverviewThe Global Nanomedicine Market is valued at USD 273.79 Billion in 2024 and is projected to reach a value of ...

"The trick was to combine anionic liposomes with small amounts of the antifungal drug Amphotericin B," reports co-first author Theresa Vogel about her doctoral thesis. Anionic liposomes are tiny fat ...

By contrast, other antifungals in this class such as amphotericin B (AmB) typically have one glycosyl group. Mandimycin is part of the family of glycosylated polyene macrolides that has provided ...

Advt Biozenta’s state-of-the-art manufacturing facility is well-equipped to produce liposomal oncology finished-dose formulations, including Amphotericin B, Peg Asparaginase, and Daunorubicin.

Fungi don’t develop resistance to this group of molecules easily, but the mandimycin discoverers were able to culture fungi in the lab that were resistant to them, including to amphotericin B ...